• Home
  • Search Results

Search Results

Open
Young Adult (18-34)
347 studies match your search
Open

Eating Disorders Genetics Study

Have you ever been concerned about your eating? We're inviting adults in the U.S. who have ever had anorexia nervosa, atypical anorexia nervosa, bulimia nervosa, binge-eating disorder, or avoidant/restrictive food intake disorder (ARFID) at any point in their life to take our survey. No official medical diagnosis is required. Common signs of different eating disorders may include: restricting the amount or type of food you eat or eating excessive amounts of food in one sitting. Some other possible signs are making yourself throw up, using diet pills or laxatives, excessively exercising, or fasting to alter your weight. Only with your help can we the causes and potential cures for these disorders. Eligible participants who complete Core Questionnaires and return their saliva sample will receive a $30 gift card.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Healthy Volunteer or General Population
  • Obesity
  • and 4 more
Visit Location
100% Remote (online, phone, text)
Open

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Open

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxo

Have you been diagnosed with large B-cell lymphoma (LBCL) and have not yet received treament? If so, you may be able to take part in a research study looking at the efficacy of giving a drug called glofitamab in combination with other drugs. The drugs are: polatuzumab vedotin (Pola) (also known as Polivy→) and rituximab (R) (also known as Rituxan→ and MabThera→), as well as a group of chemotherapy drugs, cyclophosphamide (C), doxorubicin (H), and prednisone (P) (referred to as Pola-R-CHP).

Age & Gender
  • 18 years ~ 80 years
  • Male, Female, Gender Inclusive
Study Interest
  • Glands and Hormones
Open

How does the way sugar enters the body affect brain glucose?

What factors influence how the brain takes in sugar to use it as energy? If you are between the ages of 18-45 years old and are healthy and of normal weight, you might be eligible to participate in this study to help us understand how the way sugar enters the body affects how sugar enters the brain.

Age & Gender
  • 18 years ~ 45 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Eating, Nutrition, and Metabolism
  • Healthy Volunteer or General Population
  • and 2 more
Open

Study on Hispanic/Latino Identity

Do you identify as Hispanic, Latino, and/or from Latin America? Are you an adult? If so, you may be able to participate in a study about your identity in the United States. I would love to hear about your experiences.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
Visit Location
100% Remote (online, phone, text)
Open

ARGX-113-2308

Efgartigimod has been approved by the U.S. FDA (Food and Drug Administration) as a treatment for adult patients with gMG in whom AChR-Ab's are present. However, it was not approved it for the form of gMG that is AChR Ab seronegative (antibodies not present). and therefore this study is now testing how efragtigimod works in patients without any antibodies,

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
Open

Adults with Blood Cancer

Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AK117 to patients with Leukemia

Age & Gender
  • 18 years ~ 99 years
  • Male, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Anifrolumab in HS

Do you have Hidradenitis Suppurativa (HS)? You may be eligible to participate in a research study assessing the effect of an investigational product in HS and its impact on quality of life. If eligible, and you decide to participate, you will receive the study drug study related medical evaluation and compensation for completed visits.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Minority Health
  • Rare Diseases
  • Skin, Hair, and Nails
Open

USCLC National Cutaneous Lymphoma Registry

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Neuromyelitis Optica Study

If you have NMOSD, you are between the ages of 18 and 60, and you use a smart phone, you may be able to participate in a clinical trial testing a new self-assessment tool app. Compensation provided.

Age & Gender
  • 18 years ~ 60 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research